Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) gapped up prior to trading on Monday . The stock had previously closed at $1.94, but opened at $2.12. Catabasis Pharmaceuticals shares last traded at $2.64, with a volume of 5,408,589 shares trading hands.

CATB has been the topic of several recent analyst reports. Oppenheimer Holdings, Inc. dropped their price objective on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 15th. Citigroup Inc. reiterated a “hold” rating and issued a $1.50 target price on shares of Catabasis Pharmaceuticals in a research note on Friday. HC Wainwright upped their target price on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Monday, August 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $4.00 target price on shares of Catabasis Pharmaceuticals in a research note on Wednesday, June 21st. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $4.00.

The firm’s market cap is $59.35 million. The firm has a 50-day moving average price of $1.80 and a 200 day moving average price of $1.80.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. Analysts forecast that Catabasis Pharmaceuticals, Inc. will post ($1.39) earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtu KCG Holdings LLC purchased a new stake in Catabasis Pharmaceuticals during the 2nd quarter valued at $271,000. Oppenheimer & Co. Inc. increased its holdings in shares of Catabasis Pharmaceuticals by 33.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Catabasis Pharmaceuticals in the 1st quarter worth $106,000. Institutional investors and hedge funds own 32.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.